This small cap company signed MoU with a Global Manufacturer of Electrolytes; Stock up by 10 per cent in two sessions!
This small cap company signed MoU with a Global Manufacturer of Electrolytes; Stock up by 10 per cent in two sessions!

This small cap company signed MoU with a Global Manufacturer of Electrolytes; Stock up by 10 per cent in two sessions!

The company's foray into electrolyte manufacturing complements the government's Make in India initiative

Aniket Gogate Article rating: 4.2

The company's foray into electrolyte manufacturing complements the government's Make in India initiative.

This under-the-radar micro-cap pharma stock hits upper circuit on record volume, do you hold?
This under-the-radar micro-cap pharma stock hits upper circuit on record volume, do you hold?

This under-the-radar micro-cap pharma stock hits upper circuit on record volume, do you hold?

The Stock hit the upper circuit today at Rs. 68.01, driven by an impressive 17.89 times surge in trading volume

Aniket Gogate Article rating: 4.9

Vineet Laboratories Ltd experienced a substantial upswing, hitting the upper circuit at Rs. 68.01, driven by an impressive 17.89 times surge in trading volume. The trading floor buzzed with activity as 1,87,011 units changed hands during this dynamic session.

Promoters and FIIs increased stake: This small-cap pharma company targeted Rs 750 crore revenue!
Promoters and FIIs increased stake: This small-cap pharma company targeted Rs 750 crore revenue!

Promoters and FIIs increased stake: This small-cap pharma company targeted Rs 750 crore revenue!

The company plans to launch several new products in the domestic and export markets in Q3 and Q4 of FY24.

Aniket Gogate Article rating: 5.0

FII stake increase: Foreign Institutional Investors (FIIs) have increased their stake in Lincoln Pharma from 0.63 per cent in September 2022 to 2.59 per cent in September 2023.

Promoter holding increase: The promoter holding in Lincoln Pharma has also increased from 44.09 per cent in September 2022 to 50.53 per cent in September 2023.

Stellar performance: Q1FY24 net profit skyrockets by 100 per cent; pharma stock hits back-to-back 52-week high!
Stellar performance: Q1FY24 net profit skyrockets by 100 per cent; pharma stock hits back-to-back 52-week high!

Stellar performance: Q1FY24 net profit skyrockets by 100 per cent; pharma stock hits back-to-back 52-week high!

The stock has experienced significant buying activity, soaring by over 70 per cent in the past 1 year.

Vaishnavi Chauhan Article rating: 4.1

Overall, Trident Lifeline Limited's Q1FY24 financial performance demonstrates its strong market position and ability to capitalize on growth opportunities in the pharmaceutical industry.

Multibagger stock below Rs 250: Don't miss action in this stock that has announced rights issue!
Multibagger stock below Rs 250: Don't miss action in this stock that has announced rights issue!

Multibagger stock below Rs 250: Don't miss action in this stock that has announced rights issue!

The stock has returned 71.50 per cent year to date and in just one year, it has generated multibagger gains of 224.16 per cent.

Kiran Shroff Article rating: 4.1

The stock has returned 71.50 per cent year to date and in just one year, it has generated multibagger gains of 224.16 per cent.

Top gaining stocks: These healthcare stocks surged over 10 per cent despite a sharp decline in domestic markets!
Top gaining stocks: These healthcare stocks surged over 10 per cent despite a sharp decline in domestic markets!

Top gaining stocks: These healthcare stocks surged over 10 per cent despite a sharp decline in domestic markets!

The only sector which was least affected today was the BSE Healthcare Index, which plunged 1.18 per cent to Rs 23,493.96, despite a sharp decline in the domestic market.

Kiran Shroff Article rating: 4.3

The only sector which was least affected today was the BSE Healthcare Index, which plunged 1.18 per cent to Rs 23,493.96, despite a sharp decline in the domestic market.

This pharma company received USDA approval for a generic drug which clocked over Rs 90 crore in sales, do you own it?
This pharma company received USDA approval for a generic drug which clocked over Rs 90 crore in sales, do you own it?

This pharma company received USDA approval for a generic drug which clocked over Rs 90 crore in sales, do you own it?

The company is ranked among the world’s top 100 biopharmaceutical companies and among the world’s top 50 companies in the off-patent sector.

Bhavya Rathod Article rating: 4.4

Glenmark Pharmaceuticals Ltd is an innovation-driven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses

DSIJ MINDSHARE

Mkt Commentary28-Mar, 2024

IPO Analysis29-Mar, 2024

Expert Speak29-Mar, 2024

Mindshare29-Mar, 2024

Multibaggers28-Mar, 2024

Knowledge

General26-Mar, 2024

MF25-Mar, 2024

General18-Mar, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR